Ventilator-associated Bacterial Pneumonia Clinical Trial
Official title:
The Effect of Oropharyngeal Aspiration Before Position Change on Reducing the Incidence of Ventilator-Related Pneumonia
Ventilator-associated pneumonia (VAP) is one of the healthcare-related infections that is
common in critically ill patients, prolongs hospital stay, significantly increases mortality
and additional health care costs.
Microaspiration of oropharyngeal secretions the primary pathway in the formation of VAP has
led researchers to focus on the detection of applications to prevent microbial colonization.
Continuous or intermittent oropharyngeal aspiration, open system aspiration versus closed
system aspiration, extensive oral care, oropharyngeal aspiration prior to patient positioning
are some of these applications.
When the patient is turned to position, the outbreak accumulated in the oral cavity is more
likely to move to the lower respiratory tract. In this study, it is assumed that aspiration
of oropharyngeal secretions prior to each position change will reduce the accumulation of
oral secretion in the endotracheal tube cuff and reduce aspiration of contaminated secretion
and reduce the risk of developing VIP. This randomized controlled experimental study was
planned to confirm the validity of this assumption.
This study was a randomized controlled experimental study designed to investigate the effect
of oropharyngeal aspiration on decreasing the incidence of ventilator-associated pneumonia in
patients receiving mechanical ventilation. The research was conducted between July 2015 and
April 2019 in anesthesiology and reanimation intensive care unit. The study was carried out
with 20 patients who underwent oropharyngeal aspiration as needed and 20 patients with
oropharyngeal aspiration prior to each change of position.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03894046 -
Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
|
Phase 3 | |
| Recruiting |
NCT05905055 -
P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales
|
Phase 3 | |
| Completed |
NCT03583333 -
Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)
|
Phase 3 | |
| Completed |
NCT02420366 -
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
|
||
| Completed |
NCT01292031 -
Trial of Colistin Versus Meropenem in Ventilator-associated Pneumonia (VAP) (CR-GNB)
|
Phase 3 | |
| Completed |
NCT02168946 -
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
|
Phase 3 | |
| Not yet recruiting |
NCT06087536 -
A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex
|
Phase 2 | |
| Not yet recruiting |
NCT01865266 -
The Effect of Ulinastatin on Bronchoalveolar Lavage Fluid of Inflammatory Factors in Patients With Ventilator-associated Pneumonia
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT03006679 -
A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia
|
Phase 3 |